Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: Iproceedings

Date Submitted: Jan 19, 2022
Date Accepted: Jan 19, 2022

The final, peer-reviewed published version of this preprint can be found here:

Surveillance System Evaluation for COVID-19 Vaccine–Associated Adverse Events Following Immunization (AEFI), Sindh Pakistan (2021)

Qureshi SA, Masood N, Syed A, Hussain M, Hussain K, Bhurt SA, Gadehi MA, Memon F, Bahoto MJ

Surveillance System Evaluation for COVID-19 Vaccine–Associated Adverse Events Following Immunization (AEFI), Sindh Pakistan (2021)

Iproc 2022;8(1):e36635

DOI: 10.2196/36635

Surveillance System Evaluation for COVID-19 Vaccine Associated Adverse Events following Immunization (AEFI) Sindh Pakistan 2021: Descriptive evaluation study

  • Samreen Ashraf Qureshi; 
  • Naveed Masood; 
  • Asif Syed; 
  • Mudassar Hussain; 
  • Kashif Hussain; 
  • Saeed Ahmed Bhurt; 
  • Muhammad Ali Gadehi; 
  • Fahad Memon; 
  • Muhammad Juman Bahoto

ABSTRACT

Background:

In February 2021, a mass vaccination campaign commenced in Sindh province in response to the COVID-19 epidemic. An adverse-events following immunization surveillance system (AEFI-SS) was established to monitor the adverse event following vaccination.

Objective:

We evaluated the AEFI-Surveillance System with the objectives to identify the strengths and weaknesses and suggest recommendations.

Methods:

In May-June 2021, a Descriptive evaluation study was done in Sindh-Pakistan. CDC’s updated guidelines for evaluation of surveillance system-2001 were followed to measure the qualitative, quantitative, and utility attributes of the AEFI-SS. Key stakeholders were identified based on their involvement in AEFI-SS and were interviewed. Case investigation proformas for AEFI were randomly reviewed for data quality, timeliness, and completeness. Sensitivity was calculated. Each attribute was rated as good, fair, and poor, based on a scoring legend.

Results:

The Surveillance system was useful to identify n=7147 cases of AEFI effectively. Timeliness of all AEFI cases was good and was found100%as all cases were reported within 24 hours. WHO-approved case definition was being used for the identification of AEFI cases and had a simple flow of information. AEFI-SS was good in data quality and completeness (100%), data collection tools were filled by trained medical officers. Sensitivity was 100%, predictive value positive (PVP) was not calculated due to the absence of a laboratory component. Good representativeness as >80% of the population is covered by 1004 vaccination centers. System was found stable as resources of the health department government of Sindh were being used. AEFI-SS was paper-based and deficient in a feedback mechanism.

Conclusions:

Province Sindh has an appropriate surveillance mechanism for AEFI detection and management for the ongoing COVID-19 vaccination surveillance system. The representativeness can be increased by the involvement of the private health sectors. Establishment of a feedback mechanism and digital data transformation and integration of the AEFI system with EPI is recommended.


 Citation

Please cite as:

Qureshi SA, Masood N, Syed A, Hussain M, Hussain K, Bhurt SA, Gadehi MA, Memon F, Bahoto MJ

Surveillance System Evaluation for COVID-19 Vaccine–Associated Adverse Events Following Immunization (AEFI), Sindh Pakistan (2021)

Iproc 2022;8(1):e36635

DOI: 10.2196/36635

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.